Money4Nothing ๐ฎ๐ฑ๐บ๐ธ retweeted
$LODE imho the risk/reward is pretty juicy here. I think worst case LODEโs 50% equity interest is worth $150M or essentially its current market cap.
$LQDA Yep
Replying to @deathtouch2k
Different situation with legal restrictions, but this is not being understood by the market about $lqda either. Credit to @Steven_Kiel
11
994
Everyone is focused on what $LQDA lost in the UTHR settlement.
Iโm more interested in what survived.
$222.7M in Q3 sales. 31% QoQ growth. PAH access secured. L606 still in development.
The real question: How much growth survives the PH-ILD exit?
Thatโs the opportunity.
1
18
1,546
1/4
Iโve been revisiting my $LQDA valuation following the UTHR settlement, and I think the market may be underestimating how much of the YUTREPIA business could survive.
Hereโs my bull-case math, based partly on comments coming out of the recent CHEST conference. ๐
2
11
2,310
3/4
Now the growth.
Q1โQ2 added ~$40.5M in sales.
Q2โQ3 added ~$52.3M.
Average: ~$46.4M per quarter.
Iโm assuming growth slows to just 70% of that pace, or ~$32.5M in additional quarterly revenue.
No compounding. Just adding the same dollar amount each quarter.
1
2
514
4/4
Fast-forward 8 quarters to Q3 2028:
Revenue run rate: ~$1.84B
EBITDA at 50% margin: ~$921M
Apply UTHRโs ~14.3x EV/EBITDA multiple and adjust for net debt/settlement costs:
~$13B market cap, or ~$145/share.
No L606 value included.
Bull case, not a price target. $LQDA
Money4Nothing ๐ฎ๐ฑ๐บ๐ธ retweeted
$LQDA this is my base case without knowledge of everything going on. Just plugging in Q1-Q3 numbers while knowing Q1 was a 50/50 PAH/PH-ild split & using 65/35 Q3 split. Then adding $30m/ quarter growth in PAH with a very aggressive PH-ILD drop off. Trying to be reasonably conservative and I still get $1 billion in revenue for 2027.
$LQDA This is really smart! In fact LQDAโs Q2 10-Q even mentions this and lists avoiding Hatch-Waxman as the reason. This allows to launch L-606 in ILD with no 30 months stay. Importantly, in case infringement is found in court it allows the judge flexibility
Replying to @bazooooka @Gripltandripit
The settlement is very precise if you know where to look. LQDA will file L606 as a 505b1, no 30 month stay, UTHR tries for a PI at cusp of launch, LQDA can defend (this is not "contesting" as 505b2 or PTAB would be). If LQDA later loses ebay 4 factor decides injunction vs royalty
To decide royalties and not just an injunction or NDA withdrawal as was the case with Yutrepia. It means they need more studies to support the NDA but it looks to be really worth it! $LQDA ๐
1
4
600
$LQDA Lets run some numbers. Assuming the new management 70% PAH number is correct AND we lose ALL existing ILD patients. Q3 revenues were $222M. 222 x 4 x 70% = $621.6M of PAH only annualized revenue. At 50% EBITDA margin and 13x multiple (same as UTHR) we are at
1
20
4,017
$LQDA We are at $45 share price. Now that is ignoring the fact we have a better drug and better next gen pipeline - so multiple should be higher. I think $50 is fair value for now until we have more information about new indications etc.
12
1,149
Money4Nothing ๐ฎ๐ฑ๐บ๐ธ retweeted
Also @fin_capital spoke to Dr's who literally said they would not move patients off Yutrepia no matter what the courts say about a patent. United cannot tell a Dr how to treat a patient even though they wish they could. โ at Indian Shores, FL
$LQDA New X feature for rising stocks in the screenshot.
8
624
$LQDA I think we got the best case scenario for LQDA here. I really didnโt believe they will reach an agreement. If ild is alive with L606 then this is a real win. Expect Yutrepia off label use in ILD to continue! ๐
liquidia.com/news-releases/nโฆ
2
40
2,953
$LQDA I expect the shares to climb back close to $70 - we are at a bit of a lesser position as we canโt actively market ILD (yet), but the legal overhang is gone! Eventually this is a $200+ stock. Off to the races. In another quarter when revenue growth continue stock will fly.










